Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06653322
PHASE3
A Multi-centered,Randomized,Double-blind,Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma
Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
View on ClinicalTrials.gov
Summary
The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype
Key Details
Gender
All
Age Range
12 Years - Any
Study Type
INTERVENTIONAL
Enrollment
400
Start Date
2024-11-21
Completion Date
2027-12
Last Updated
2025-12-10
Healthy Volunteers
No
Conditions
Interventions
DRUG
HR-1703
HR-1703 will be administered by SC injection.
DRUG
Placebo
Matching Placebo will be administered by the SC injection.
Locations (1)
West China School of Medicine West China Hospital of Sichuan University
Chengdu, Sichuan, China